Jefferies Remains a Hold on Novartis AG (NOVN)
Jefferies analyst Benjamin Jackson CFA maintained a Hold rating on Novartis AG today and set a price target of CHF110.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Jackson CFA is a 3-star analyst with an average return of 7.7% and a 56.25% success rate. Jackson CFA covers the Healthcare sector, focusing on stocks such as Sanofi, Galderma Group AG, and Novartis AG.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novartis AG with a CHF115.33 average price target.
Based on Novartis AG’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of CHF14.36 billion and a net profit of CHF3.93 billion. In comparison, last year the company earned a revenue of CHF13.17 billion and had a net profit of CHF3.19 billion
Read More on CH:NOVN:
Disclaimer & DisclosureReport an Issue
- Avidity Biosciences announces expected record date for spin-off
- Novartis AG: Visible Earnings, Supportive Guidance and Attractive Risk‑Reward Underpin Buy Rating
- Novartis initiated with a Buy at Citi
- AI Daily: Nvidia invests $2B in CoreWeave
- Drugmakers use AI to help progress through trials, submissions, Reuters says
